TNF and myelodysplastic syndrome: While conventional immunosuppressants, such as cyclophosphamide, are often the standard of care for primary PAN, secondary forms may respond better to more specific agents: anti-TNF alpha for DADA2, JAK inhibitors for VEXAS, and targeted MDS treatment for PAN associated with MDS or allogeneic stem cell transplantation.